506 results on '"Cher, Michael L."'
Search Results
2. Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial
3. Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)
4. Determinants of active surveillance uptake in a diverse population‐based cohort of men with low‐risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS)
5. Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy
6. Determinants of active surveillance uptake in a diverse population-based cohort of men with low-risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS).
7. Can MRI Help Inform Which Men With a History of Multifocal High-Grade Prostatic Intraepithelial Neoplasia or Atypical Small Acinar Proliferation Remain at an Elevated Risk for Clinically Significant Prostate Cancer?
8. A novel cross-talk between CXCR4 and PI4KIIIα in prostate cancer cells
9. Does Urologist-level Utilization of Active Surveillance for Low-risk Prostate Cancer Correspond with Utilization of Active Surveillance for Small Renal Masses?
10. Maspin Expression Inhibits Osteolysis, Tumor Growth, and Angiogenesis in a Model of Prostate Cancer Bone Metastasis
11. Does Urologist-level Utilization of Active Surveillance for Low-risk Prostate Cancer Correspond with Utilization of Active Surveillance for Small Renal Masses?
12. Pathologically Node-Positive Prostate Cancer: Casting for Cure When the Die Is Cast?
13. Prospective assessment of positioning-related pain in robotic urologic surgery
14. Supplementary Figure Legends from Transcriptional Regulation of CXCR4 in Prostate Cancer: Significance of TMPRSS2-ERG Fusions
15. Supplementary Data from Transcriptional Regulation of CXCR4 in Prostate Cancer: Significance of TMPRSS2-ERG Fusions
16. Data from Transcriptional Regulation of CXCR4 in Prostate Cancer: Significance of TMPRSS2-ERG Fusions
17. PD21-02 ASSESSING THE GENERALIZABILITY OF RANDOMIZED EVIDENCE BY COMPARING RESULTS FROM A CLINICAL TRIAL AND ESTABLISHED QUALITY IMPROVEMENT COLLABORATIVE: RESULTS FROM G-MINOR AND MUSIC
18. Supplementary Figures 1-4 from ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells
19. Data from Cryotherapy with Concurrent CpG Oligonucleotide Treatment Controls Local Tumor Recurrence and Modulates HER2/neu Immunity
20. Data Supplement from Cryotherapy with Concurrent CpG Oligonucleotide Treatment Controls Local Tumor Recurrence and Modulates HER2/neu Immunity
21. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model
22. Upgrading on Per Protocol versus For Cause surveillance prostate biopsies: An opportunity to decreasing the burden of active surveillance.
23. Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth
24. Determining the impact of genomic classifier testing on patient-reported quality of life after prostatectomy: Results from the G-MINOR randomized trial.
25. IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
26. The Use and Short-term Outcomes of Active Surveillance in Men With National Comprehensive Cancer Network Favorable Intermediate-risk Prostate Cancer: The Initial Michigan Urological Surgery Improvement Collaborative Experience
27. MUSIC: Patterns of Care in the Radiographic Staging of Men with Newly Diagnosed Low Risk Prostate Cancer
28. Prostate cancer diagnosis, staging and survival
29. Infection-Related Hospital Admissions After Prostate Biopsy in United States Men
30. A Roadmap for Improving the Management of Favorable Risk Prostate Cancer
31. Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study
32. Trials in the Key of G: Building Level 1 Evidence on the Real-world Effectiveness of Prostate Biomarkers
33. Practice-Level Variation in the Decision to Biopsy Prostate Imaging-Reporting and Data System 3 Lesions in Favorable-Risk Prostate Cancer Patients
34. Matrix Metalloproteinaes and Bone Metastasis
35. Avoidance of androgen deprivation therapy in radiorecurrent prostate cancer as a clinically meaningful endpoint for salvage cryoablation
36. Prostate cancer family history and eligibility for active surveillance: a systematic review of the literature
37. Practice- vs Physician-Level Variation in Use of Active Surveillance for Men With Low-Risk Prostate Cancer: Implications for Collaborative Quality Improvement
38. Appropriateness Criteria for Active Surveillance of Prostate Cancer
39. PTEN Regulates PDGF Ligand Switch for β-PDGFR Signaling in Prostate Cancer
40. Five-year follow-up study of a population-based prospective cohort of men with low-risk prostate cancer: the treatment options in prostate cancer study (TOPCS): study protocol
41. Association of lymph node yield with overall survival in patients with pathologically node negative prostate cancer
42. Editorial Commentary
43. Urologists’ Perceptions of Active Surveillance and Their Recommendations for Low-risk Prostate Cancer Patients
44. Phase II Trial of Capecitabine and Weekly Docetaxel for Metastatic Castrate Resistant Prostate Cancer
45. Bone-induced c-kit expression in prostate cancer: A driver of intraosseous tumor growth
46. Does the type of cryoprobe affect oncological and functional outcomes in men with clinically localized prostate cancer treated with primary whole gland prostate cryoablation?
47. The added influence of genomics and post‐MRI confirmatory biopsy results to MRI results alone on medical decision making for men with favorable risk prostate cancer being considered for active surveillance.
48. Host matrix metalloproteinase-9 contributes to tumor vascularization without affecting tumor growth in a model of prostate cancer bone metastasis
49. Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis
50. Heterogeneous Activation of MMP-9 Due to Prostate Cancer-Bone Interaction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.